Amicus Therapeutics Inc (LTS:0HF9)
$ 9.978 -0.0808 (-0.8%) Market Cap: 2.98 Bil Enterprise Value: 3.18 Bil PE Ratio: 0 PB Ratio: 16.66 GF Score: 81/100

Amicus Therapeutics Inc at JPMorgan Healthcare Conference Transcript

Jan 14, 2020 / 04:30PM GMT
Release Date Price: $9.88
Anupam Rama
JP Morgan Chase & Co, Research Division - VP and Analyst

Okay. We'll go ahead and get started. Welcome to the Tuesday morning of the 2020 JPMorgan Healthcare Conference. My name is Anupam Rama. I'm one of the senior biotech analysts here at JPMorgan. I'm joined by Tessa Romero and Matt Bannon from the team. Our next presenting company is Amicus Therapeutics, and speaking on behalf of the company is CEO, John Crowley. John?

John F. Crowley
Amicus Therapeutics, Inc. - Chairman & CEO

Great. Thank you, Anupam, and good morning, everybody. Thanks for being here. We'll be making forward-looking statements, so I'll reference you to Slide #2. We describe Amicus as a rare company. And this slide will give you an overview of some of the key pieces of the company that we've been building and where we are today and I think, in large measure, why we're so excited about 2020. So again, the cornerstone of our success with Galafold, our precision small medicine for Fabry disease; our world-class biologic now in a Phase III study fully enrolled for Pompe

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot